Exact Sciences Corporation is a global advanced cancer diagnostics company. Co. provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Co. is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. Co.'s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The EXAS stock yearly return is shown above.
The yearly return on the EXAS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2024 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EXAS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|